isoprenaline Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Isoproterenol (trade names Medihaler-Iso and Isuprel) is a medication used for the treatment of bradycardia (slow heart rate), heart block, and rarely for asthma. Isoproterenol is a non-selective β adrenoreceptor agonist and TAAR1 agonist that is the isopropylaminomethyl analog of epinephrine. Isoprenaline's effects on the cardiovascular system (non-selective) relate to its actions on cardiac β1 receptors and β2 receptors on smooth muscle within the tunica media of arterioles. Isoprenaline has positive inotropic and chronotropic effects on the heart. β2 adrenoceptor stimulation in arteriolar smooth muscle induces vasodilation. Its inotropic and chronotropic effects elevate systolic blood pressure, while its vasodilatory effects tend to lower diastolic blood pressure. The overall effect is to decrease mean arterial pressure due to the β2 receptors' vasodilation. The adverse effects of isoprenaline are also related to the drug's cardiovascular effects. Isoprenaline can produce tachycardia (an elevated heart rate), which predisposes patients to cardiac arrhythmias.   NCATS

Chemistry

More Chemistry

Pharmacology

Combination drugs

( phenylephrine (Prefrin), isoprenaline )
|
( acetylcysteine (mucomyst), isoprenaline )

Alternative names

1-(3,4-dihydroxyphenyl)-2-isopropylaminoethanol | 1-(3,4-dihydroxyphenyl)-2-(isopropylamino)ethanol | 3,4-dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol | aerolone | alpha-(isopropylaminomethyl)protocatechuyl alcohol | dl-isoprenaline hcl | dl-isoprenaline hydrochloride | dl-isoproterenol | imuprel | isoprenalin | isoprenalina | isoprenaline | (+-)-isoprenaline | (±)-isoprenaline | isoprenaline sulfate | isoprenalinum | isopropylarterenol hcl | isopropylarterenol sulfate | isopropyl noradrenaline | isoproterenol | (+-)-isoproterenol | (±)-isoproterenol | isoproterenol hcl | isoproterenol hydrochloride | isoproterenol sulfate | isuprel | l-isoprenaline hcl | medihaler-iso | n-isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine | n-isopropylnoradrenaline | n-isopropylnorepinephrine | n-isopropyl-β-dihydroxyphenyl-β-hydroxyethylamine | norisodrine | norisodrine aerotrol | vapo-iso | α-(isopropylaminomethyl)protocatechuyl alcohol

Organizations (51)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (34)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (4)


 

Adams-Stokes Syndrome (approved 1956)

Bronchial Spasm (approved 1956)

Heart Arrest (approved 1956)

Heart Block (approved 1956)

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Atrial Fibrillation (Phase 2)

Autonomic Nervous System Diseases (Phase 1)

Dopamine beta-Hydroxylase (Phase 1)

Healthy Volunteers (Phase 1)

Hematuria (Phase 2/Phase 3)

Hypotension, Orthostatic (Phase 1)

Kidney Calculi (Phase 2/Phase 3)

Lipoma (Phase 1/Phase 2)

Neoplasms (Phase 2/Phase 3)

Obesity (Early Phase 1)

Orthostatic Intolerance (Phase 1)

Ureteroscopy (Phase 2)

Vasodilation (Early Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue